Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Combination of Ixekizumab and Tirzepatide Results in Enhanced Disease Management Compared to Ixekizumab Monotherapy in Adults with Psoriatic Arthritis and Overweight or Obesity

  • By

  • Joseph F. Merola

  • Cynthia E. Kartman

  • Peter Fischer

  • Luna Sun

  • Anabela Cardoso

  • Mark C. Genovese

  • Alexis Ogdie

  • June 11, 2026

Share

  • 1

    Ixekizumab combined with Tirzepatide shows improved disease management in adults with Psoriatic Arthritis and overweight or obesity.

  • 2

    The study highlights the effectiveness of the combination therapy over Ixekizumab monotherapy.

  • 3

    Authors include experts from the University of Texas Southwestern Medical Center and Eli Lilly and Company.

  • 4

    The article has been accepted for publication and is undergoing peer review.

  • 5

    Disclosure forms for the authors are available, indicating potential conflicts of interest.

Original Source(s)

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

  • by Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie

  • June 11, 2026

Related Content

Associations of Lifestyle-Related Factors and Psoriatic Arthritis Disease Activity: The Dutch South West Psoriatic Arthritis Study

Ultrasound assessment of temporomandibular disorders: comparative analysis between inflammatory and degenerative patterns in rheumatic and non-rheumatic patients

PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease